myTomorrows, a global health technology company, and Scout Clinical, a leader in biopharmaceutical services, announced a strategic partnership aimed at transforming cross-border patient recruitment for clinical trials. The collaboration, revealed on April 15, 2025, addresses the significant logistical, financial, and emotional barriers that have traditionally limited international participation in clinical research.
The partnership integrates myTomorrows' AI-powered trial matching capabilities with Scout's comprehensive patient support services to create a seamless experience for patients seeking access to experimental treatments regardless of geographic location.
Breaking Down Barriers to Clinical Trial Access
Cross-border clinical research has historically faced numerous challenges that limit patient participation and slow the development of new therapies. These obstacles include fragmented information systems, regulatory differences between countries, complex visa requirements, and data privacy concerns. For patients with rare diseases or those seeking specialized treatments, these barriers can significantly restrict access to potentially life-saving clinical trials.
"By removing barriers and overcoming the geographic silos of traditional trials, we provide every patient, regardless of location or personal circumstances, with a real opportunity to participate," said Michel van Harten, MD, CEO of myTomorrows. "Our inventive approach directly addresses the industry's critical need to expand patient access whilst easing logistical burdens for patients and their families."
The partnership creates a comprehensive support system that begins with myTomorrows' Patient Navigator team identifying appropriate trial options and conducting pre-screening. Once matched, Scout Clinical takes over the logistical aspects, providing services including:
- Travel arrangements for patients and caregivers
- Expense reimbursements and pre-funded debit cards for out-of-pocket costs
- Short-term lodging and long-term housing for relocated patients
- Visa assistance and entry/exit support
- Ongoing logistical coordination throughout the trial
Technology-Driven Approach to Patient Recruitment
At the core of this partnership is the integration of advanced technologies to streamline the patient recruitment process. myTomorrows' AI platform can identify potentially eligible trial options within seconds, delivering a 90% reduction in eligibility criteria checking time compared to manual processes. This dramatically reduces the administrative burden on physicians while enhancing screening efficiency.
Scout's contribution focuses on expanding global patient reach, diversifying enrollment pools, and streamlining trial operations. Together, the companies deliver faster, more effective recruitment while maintaining compliance with international data protection regulations.
"Our partnership with myTomorrows is a win-win for all stakeholders across the clinical trial ecosystem," said Scout CEO Moisha Platto. "By addressing key barriers early, sites can efficiently manage international patient intake and expand their reach. Patients will benefit from a clearer understanding of the process and access to a wider range of potential treatment options."
Impact on Clinical Research and Patient Care
The collaboration addresses several critical challenges in the clinical research landscape:
Expanded Patient Access
By facilitating cross-border participation, the partnership opens clinical trials to a more diverse patient population, potentially accelerating recruitment timelines and improving the generalizability of research findings.
Reduced Patient Burden
The comprehensive support services alleviate the financial, logistical, and emotional strain on patients and caregivers, potentially improving retention rates and overall trial experience.
Accelerated Drug Development
Faster recruitment and improved retention may lead to more efficient clinical trials, potentially bringing new treatments to market more quickly.
Enhanced Trial Diversity
By removing geographic barriers, trials can achieve greater demographic and genetic diversity among participants, addressing a long-standing challenge in clinical research.
The partnership represents a significant advancement in making clinical trials more accessible globally. myTomorrows has already demonstrated its impact, having helped more than 15,300 patients and 2,400 physicians across 240+ sites in over 128 countries. Scout brings extensive operational experience in 109 countries and a deep understanding of international regulations.
As clinical research continues to globalize, this collaboration sets a new standard for patient-centered trial recruitment, potentially transforming how patients access experimental treatments while accelerating the development of new therapies for unmet medical needs.
